

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 June 2020 (04.06.2020)



(10) International Publication Number
WO 2020/113151 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) A61K 31/76 (2006.01)
A61K 31/7088 (2006.01) A61K 35/761 (2015.01)
A61K 31/7105 (2006.01) A61K 35/763 (2015.01)

(21) International Application Number:

PCT/US2019/063838

(22) International Filing Date:

29 November 2019 (29.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/773,119 29 November 2018 (29.11.2018) US

(71) Applicant: VIROGIN BIOTECH CANADA LTD
[CA/CA]; 308-4800 Wesbrook Mall, Vancouver, British
Columbia V6S 2L9 (CA).

(72) Inventors: JIA, William; 308-4800 Wesbrook Mall,
Vancouver, British Columbia V6S 2L9 (CA). CHOUL-
JENKO, Dmitry, V.; 308-4800 Wesbrook Mall, Van-
couver, British Columbia V6S 2L9 (CA). LEE, I-Fang;
308-4800 Wesbrook Mall, Vancouver, British Columbia
V6S 2L9 (CA). MURAD, Yanal, M.; 308-4800 Wesbrook
Mall, Vancouver, British Columbia V6S 2L9 (CA). LIU,
Xiaohu; 308-4800 Wesbrook Mall, Vancouver, British Co-
lumbia V6S 2L9 (CA). LIU, Guoyu; 308-4800 Wesbrook
Mall, Vancouver, British Columbia V6S 2L9 (CA). BU,
Xuexian; 308-4800 Wesbrook Mall, Vancouver, British
Columbia V6S 2L9 (CA). DELWAR, Zahid; 308-4800
Wesbrook Mall, Vancouver, British Columbia V6S 2L9
(CA).

(74) Agent: MCMASTERS, David, D.; Kurious LLC, 2400
NW 80th Street, PMB 138, Seattle, Washington 98117
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: HSV VECTOR WITH REDUCED NEUROTOXICITY




FIG. 1

(57) Abstract: Recombinant herpes simplex viruses are provided having a modified oncolytic herpes virus genome, wherein the modified herpes virus genome has at least one miRNA target sequence operably linked to a first or to a first and a second copy of an ICP34.5 gene. Also provided are pharmaceutical compositions having such recombinant herpes simplex viruses, as well as methods of using such compositions in the treatment of subjects having cancer.

WO 2020/113151 A1